CN101568536B - 作为食欲素受体拮抗剂的2-氮杂-双环[3.1.0]己烷衍生物 - Google Patents
作为食欲素受体拮抗剂的2-氮杂-双环[3.1.0]己烷衍生物 Download PDFInfo
- Publication number
- CN101568536B CN101568536B CN2007800483236A CN200780048323A CN101568536B CN 101568536 B CN101568536 B CN 101568536B CN 2007800483236 A CN2007800483236 A CN 2007800483236A CN 200780048323 A CN200780048323 A CN 200780048323A CN 101568536 B CN101568536 B CN 101568536B
- Authority
- CN
- China
- Prior art keywords
- thiazole
- bicyclo
- methyl
- aza
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *c1cccc(NC(N)=S)c1 Chemical compound *c1cccc(NC(N)=S)c1 0.000 description 2
- YUOJOVAEYMMGIG-UHFFFAOYSA-N Bc([s]1)c(C(OC)=O)nc1Br Chemical compound Bc([s]1)c(C(OC)=O)nc1Br YUOJOVAEYMMGIG-UHFFFAOYSA-N 0.000 description 1
- SOFSHHXZJORZEJ-UHFFFAOYSA-N Bc1c(C(O)=O)nc(N(C)C)[s]1 Chemical compound Bc1c(C(O)=O)nc(N(C)C)[s]1 SOFSHHXZJORZEJ-UHFFFAOYSA-N 0.000 description 1
- DVENXGORJBTFNY-UHFFFAOYSA-N Bc1c(C(OC)=O)nc(C2CC2)[s]1 Chemical compound Bc1c(C(OC)=O)nc(C2CC2)[s]1 DVENXGORJBTFNY-UHFFFAOYSA-N 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N C1COc2ccccc2C1 Chemical compound C1COc2ccccc2C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- FEJLPMVSVDSKHJ-UHFFFAOYSA-N CC(C)CC[N+]([O-])=O Chemical compound CC(C)CC[N+]([O-])=O FEJLPMVSVDSKHJ-UHFFFAOYSA-N 0.000 description 1
- BMKWWNQZJBDTPD-UHFFFAOYSA-N COC(C1=CC(OCC#C)=CCC1)=O Chemical compound COC(C1=CC(OCC#C)=CCC1)=O BMKWWNQZJBDTPD-UHFFFAOYSA-N 0.000 description 1
- NCYVCBWYMKECRH-UHFFFAOYSA-N COC(c1c(C=CCO2)c2ccc1)=O Chemical compound COC(c1c(C=CCO2)c2ccc1)=O NCYVCBWYMKECRH-UHFFFAOYSA-N 0.000 description 1
- SVEZOHPWBLWBNO-UHFFFAOYSA-N COC(c1c2[s]cnc2ccc1)=O Chemical compound COC(c1c2[s]cnc2ccc1)=O SVEZOHPWBLWBNO-UHFFFAOYSA-N 0.000 description 1
- VZDNXXPBYLGWOS-UHFFFAOYSA-N COC(c1cc(N)ccc1)=O Chemical compound COC(c1cc(N)ccc1)=O VZDNXXPBYLGWOS-UHFFFAOYSA-N 0.000 description 1
- YKUCHDXIBAQWSF-UHFFFAOYSA-N COC(c1cc(O)ccc1)=O Chemical compound COC(c1cc(O)ccc1)=O YKUCHDXIBAQWSF-UHFFFAOYSA-N 0.000 description 1
- IIPJWNFOLPDTEQ-UHFFFAOYSA-N NC(C1CC1)=S Chemical compound NC(C1CC1)=S IIPJWNFOLPDTEQ-UHFFFAOYSA-N 0.000 description 1
- IQGMRVWUTCYCST-UHFFFAOYSA-N Nc(cccc1C(O)=O)c1O Chemical compound Nc(cccc1C(O)=O)c1O IQGMRVWUTCYCST-UHFFFAOYSA-N 0.000 description 1
- MSTDXOZUKAQDRL-UHFFFAOYSA-N O=C1c2ccccc2OCC1 Chemical compound O=C1c2ccccc2OCC1 MSTDXOZUKAQDRL-UHFFFAOYSA-N 0.000 description 1
- QMVZMKJWEQFJDP-UHFFFAOYSA-N OC(c1c(C=CCO2)c2ccc1)=O Chemical compound OC(c1c(C=CCO2)c2ccc1)=O QMVZMKJWEQFJDP-UHFFFAOYSA-N 0.000 description 1
- LOFOWPRKKPHPDW-UHFFFAOYSA-N OC(c1c2OCCCc2ccc1)=O Chemical compound OC(c1c2OCCCc2ccc1)=O LOFOWPRKKPHPDW-UHFFFAOYSA-N 0.000 description 1
- DATHVLKSETWACZ-UHFFFAOYSA-N OC(c1c2[o]c(S)nc2ccc1)=O Chemical compound OC(c1c2[o]c(S)nc2ccc1)=O DATHVLKSETWACZ-UHFFFAOYSA-N 0.000 description 1
- ORSZGLLQNYSMNO-UHFFFAOYSA-N OC(c1c2[s]cnc2ccc1)=O Chemical compound OC(c1c2[s]cnc2ccc1)=O ORSZGLLQNYSMNO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2006055042 | 2006-12-28 | ||
| WOPCT/IB2006/055042 | 2006-12-28 | ||
| IBPCT/IB2006/055042 | 2006-12-28 | ||
| PCT/IB2007/055326 WO2008081399A2 (en) | 2006-12-28 | 2007-12-28 | 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101568536A CN101568536A (zh) | 2009-10-28 |
| CN101568536B true CN101568536B (zh) | 2011-12-28 |
Family
ID=39343649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800483236A Expired - Fee Related CN101568536B (zh) | 2006-12-28 | 2007-12-28 | 作为食欲素受体拮抗剂的2-氮杂-双环[3.1.0]己烷衍生物 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8288435B2 (OSRAM) |
| EP (1) | EP2094690B1 (OSRAM) |
| JP (1) | JP2010514751A (OSRAM) |
| KR (1) | KR20090094168A (OSRAM) |
| CN (1) | CN101568536B (OSRAM) |
| AR (1) | AR064561A1 (OSRAM) |
| AT (1) | ATE505467T1 (OSRAM) |
| AU (1) | AU2007340944B2 (OSRAM) |
| BR (1) | BRPI0720876A2 (OSRAM) |
| CA (1) | CA2669821A1 (OSRAM) |
| CL (1) | CL2007003827A1 (OSRAM) |
| CY (1) | CY1111705T1 (OSRAM) |
| DE (1) | DE602007013937D1 (OSRAM) |
| DK (1) | DK2094690T3 (OSRAM) |
| ES (1) | ES2364297T3 (OSRAM) |
| HR (1) | HRP20110509T1 (OSRAM) |
| MA (1) | MA31000B1 (OSRAM) |
| MX (1) | MX2009006860A (OSRAM) |
| MY (1) | MY157344A (OSRAM) |
| NO (1) | NO20092762L (OSRAM) |
| NZ (1) | NZ578642A (OSRAM) |
| PL (1) | PL2094690T3 (OSRAM) |
| PT (1) | PT2094690E (OSRAM) |
| RU (1) | RU2460732C2 (OSRAM) |
| SI (1) | SI2094690T1 (OSRAM) |
| TW (1) | TW200833328A (OSRAM) |
| WO (1) | WO2008081399A2 (OSRAM) |
| ZA (1) | ZA200905229B (OSRAM) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2007002809A1 (es) * | 2006-09-29 | 2008-04-18 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas |
| US8133901B2 (en) | 2006-12-01 | 2012-03-13 | Actelion Pharmaceuticals Ltd. | 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors |
| CL2008000836A1 (es) * | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| JP2010528007A (ja) | 2007-05-23 | 2010-08-19 | メルク・シャープ・エンド・ドーム・コーポレイション | シクロプロピルピロリジンオレキシン受容体アンタゴニスト |
| US8288411B2 (en) * | 2007-09-24 | 2012-10-16 | Actelion Pharmaceuticals Ltd. | Pyrrolidines and piperidines as orexin receptor antagonists |
| WO2009104155A1 (en) * | 2008-02-21 | 2009-08-27 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[2.2.1]heptane derivatives |
| JP2011519849A (ja) * | 2008-04-30 | 2011-07-14 | アクテリオン ファーマシューティカルズ リミテッド | ピペリジン及びピロリジン化合物 |
| CN102164896A (zh) * | 2008-10-14 | 2011-08-24 | 埃科特莱茵药品有限公司 | 苯乙基酰胺衍生物及其杂环类似物 |
| EP2275421A1 (en) * | 2009-07-15 | 2011-01-19 | Rottapharm S.p.A. | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction |
| SG181502A1 (en) | 2009-12-29 | 2012-07-30 | Suven Life Sciences Ltd | Alpha4beta2 neuronal nicotinic acetylcholine receptor ligands |
| EP2626350B1 (en) * | 2010-09-22 | 2015-04-15 | Eisai R&D Management Co., Ltd. | Cyclopropane compound |
| US9012489B2 (en) * | 2011-08-03 | 2015-04-21 | Boehringer Ingelheim International Gmbh | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament |
| WO2013050938A1 (en) | 2011-10-04 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives |
| ITMI20112329A1 (it) * | 2011-12-21 | 2013-06-22 | Rottapharm Spa | Nuovi derivati spiro amminici |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| ES2672732T3 (es) | 2012-02-07 | 2018-06-15 | Eolas Therapeutics Inc. | Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina |
| ITMI20120424A1 (it) * | 2012-03-19 | 2013-09-20 | Rottapharm Spa | Composti chimici |
| MY169986A (en) * | 2012-06-04 | 2019-06-19 | Idorsia Pharmaceuticals Ltd | Benzimidazole-proline derivatives |
| EP2875029B8 (en) * | 2012-07-18 | 2021-12-15 | University of Notre Dame du Lac | 5,5-heteroaromatic anti-infective compounds |
| AR092955A1 (es) | 2012-10-10 | 2015-05-06 | Actelion Pharmaceuticals Ltd | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona |
| WO2014141065A1 (en) | 2013-03-12 | 2014-09-18 | Actelion Pharmaceuticals Ltd | Azetidine amide derivatives as orexin receptor antagonists |
| TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
| TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途 |
| TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| NZ721438A (en) | 2013-12-03 | 2021-12-24 | Idorsia Pharmaceuticals Ltd | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists |
| JP6421185B2 (ja) | 2013-12-04 | 2018-11-07 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ベンゾイミダゾール−プロリン誘導体の使用 |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| UY36272A (es) | 2014-08-13 | 2016-02-29 | Eolas Therapeutics Inc | Difluoropirrolidinas como moduladores de los receptores de orexinas |
| EP3191468B1 (en) | 2014-09-11 | 2018-12-12 | Janssen Pharmaceutica NV | Substituted 2-azabicycles and their use as orexin receptor modulators |
| WO2016063995A1 (en) | 2014-10-23 | 2016-04-28 | Eisai R&D Management Co., Ltd. | Compositions and methods for treating insomnia |
| CN106588900A (zh) * | 2015-10-20 | 2017-04-26 | 北京康辰医药科技有限公司 | 一种苯并双环化合物或其药学上可接受的盐、药物组合物及其应用 |
| TWI710557B (zh) | 2016-02-12 | 2020-11-21 | 美商伊歐拉斯治療學公司 | 作為食慾素受體調節劑之經鹵素取代之六氫吡啶 |
| WO2017144015A1 (zh) * | 2016-02-26 | 2017-08-31 | 江苏恒瑞医药股份有限公司 | 一种新毒素及其中间体的制备方法 |
| WO2017194548A1 (en) | 2016-05-10 | 2017-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
| PT3619199T (pt) | 2017-05-03 | 2021-10-01 | Idorsia Pharmaceuticals Ltd | Preparação de derivados de ácido 2-([1,2,3]triazol-2-il)- benzoico |
| WO2019057946A1 (en) | 2017-09-25 | 2019-03-28 | F. Hoffmann-La Roche Ag | MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS |
| WO2020007964A1 (en) | 2018-07-05 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives |
| WO2020007977A1 (en) | 2018-07-06 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 7-trifluoromethyl-[1,4]diazepan derivatives |
| WO2020099511A1 (en) | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
| US12059408B2 (en) | 2020-08-13 | 2024-08-13 | Boehringer Ingelheim International Gmbh | Treatment of cognitive impairment associated with schizophrenia |
| WO2022078927A1 (en) | 2020-10-13 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Process of reworking |
| CN116783182B (zh) * | 2021-02-02 | 2025-08-29 | 南京明德新药研发有限公司 | 四氢吡咯并环化合物及其应用 |
| TW202400149A (zh) | 2022-05-13 | 2024-01-01 | 瑞士商愛杜西亞製藥有限公司 | 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物 |
| WO2025224168A1 (en) | 2024-04-24 | 2025-10-30 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1633433A (zh) * | 2001-05-05 | 2005-06-29 | 史密斯克莱·比奇曼公司 | N－芳酰基环胺 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH621126A5 (OSRAM) | 1974-02-07 | 1981-01-15 | Plantex Ltd | |
| AU2381995A (en) | 1994-04-29 | 1995-11-29 | Pharmacia & Upjohn Company | Methanol derivatives for treatment of retroviral infections especially hiv infections |
| EP1289955B1 (en) | 2000-06-16 | 2005-04-13 | Smithkline Beecham Plc | Piperidines for use as orexin receptor antagonists |
| CA2429258A1 (en) | 2000-11-20 | 2002-06-13 | Scios Inc. | Piperidine/piperazine-type inhibitors of p38 kinase |
| EP1353918B1 (en) | 2000-11-28 | 2005-01-12 | Smithkline Beecham Plc | Morpholine derivatives as antagonists of orexin receptors |
| US20040192673A1 (en) | 2001-05-05 | 2004-09-30 | Pascale Gaillard | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| GB0111341D0 (en) | 2001-05-10 | 2001-07-04 | Bp Chem Int Ltd | Novel polymerisation catalysts |
| GB0115862D0 (en) * | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| BR0210609A (pt) | 2001-06-28 | 2004-07-20 | Smithkline Beecham Plc | Derivados de amina cìclica n-aroila como antagonistas do receptor da orexina |
| GB0124463D0 (en) * | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
| GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
| US6727247B2 (en) * | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
| GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| GB0130335D0 (en) * | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| WO2004026866A1 (en) | 2002-09-18 | 2004-04-01 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
| GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225884D0 (en) * | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| CN100432056C (zh) * | 2003-03-26 | 2008-11-12 | 埃科特莱茵药品有限公司 | 四氢异喹啉基乙酰胺衍生物作为阿立新受体拮抗剂的应用 |
| WO2004096780A1 (en) * | 2003-04-28 | 2004-11-11 | Actelion Pharmaceuticals Ltd | Quinoxalinone-3- one derivatives as orexin receptor antagonists |
| PT1751111E (pt) * | 2004-03-01 | 2015-04-01 | Actelion Pharmaceuticals Ltd | Derivados de 1,2,3,4-tetrahidroisoquinolina substituída |
| US20060014733A1 (en) | 2004-07-19 | 2006-01-19 | Pfizer Inc | Histamine-3 agonists and antagonists |
| US7994336B2 (en) | 2006-08-15 | 2011-08-09 | Actelion Pharmaceuticals Ltd. | Azetidine compounds as orexin receptor antagonists |
| CL2007002809A1 (es) | 2006-09-29 | 2008-04-18 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas |
| US8133901B2 (en) | 2006-12-01 | 2012-03-13 | Actelion Pharmaceuticals Ltd. | 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors |
| CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| JP2010526869A (ja) | 2007-05-14 | 2010-08-05 | アクテリオン ファーマシューティカルズ リミテッド | ２−シクロプロピル−チアゾール誘導体 |
| AU2008257411B2 (en) | 2007-05-23 | 2012-04-26 | Merck Sharp & Dohme Corp. | Pyridyl piperidine orexin receptor antagonists |
| JP2010528007A (ja) | 2007-05-23 | 2010-08-19 | メルク・シャープ・エンド・ドーム・コーポレイション | シクロプロピルピロリジンオレキシン受容体アンタゴニスト |
| US8106215B2 (en) | 2007-07-03 | 2012-01-31 | Actelion Pharmaceuticals Ltd. | 3-aza-bicyclo[3.3.0]octane compounds |
| US8288429B2 (en) | 2007-07-27 | 2012-10-16 | Actelion Pharmaceuticals Ltd. | 2-aza-bicyclo[3.3.0]octane derivatives |
| AR067665A1 (es) | 2007-07-27 | 2009-10-21 | Actelion Pharmaceuticals Ltd | Derivados de trans-3- aza-biciclo ( 3.1.0) hexano |
| US8288411B2 (en) | 2007-09-24 | 2012-10-16 | Actelion Pharmaceuticals Ltd. | Pyrrolidines and piperidines as orexin receptor antagonists |
| WO2009104155A1 (en) | 2008-02-21 | 2009-08-27 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[2.2.1]heptane derivatives |
| JP2011519849A (ja) | 2008-04-30 | 2011-07-14 | アクテリオン ファーマシューティカルズ リミテッド | ピペリジン及びピロリジン化合物 |
| TW200940822A (en) * | 2009-05-07 | 2009-10-01 | Wan Chi Steel Ind Co Ltd | Water wheel mechanism with sun-and-planet type blade |
-
2007
- 2007-12-27 CL CL200703827A patent/CL2007003827A1/es unknown
- 2007-12-27 AR ARP070105930A patent/AR064561A1/es not_active Application Discontinuation
- 2007-12-27 TW TW096150631A patent/TW200833328A/zh unknown
- 2007-12-28 RU RU2009128739/04A patent/RU2460732C2/ru not_active IP Right Cessation
- 2007-12-28 AU AU2007340944A patent/AU2007340944B2/en not_active Expired - Fee Related
- 2007-12-28 MX MX2009006860A patent/MX2009006860A/es active IP Right Grant
- 2007-12-28 SI SI200730639T patent/SI2094690T1/sl unknown
- 2007-12-28 EP EP07859531A patent/EP2094690B1/en active Active
- 2007-12-28 AT AT07859531T patent/ATE505467T1/de active
- 2007-12-28 MY MYPI20092751A patent/MY157344A/en unknown
- 2007-12-28 CA CA002669821A patent/CA2669821A1/en not_active Abandoned
- 2007-12-28 DK DK07859531.1T patent/DK2094690T3/da active
- 2007-12-28 KR KR1020097015732A patent/KR20090094168A/ko not_active Ceased
- 2007-12-28 PL PL07859531T patent/PL2094690T3/pl unknown
- 2007-12-28 JP JP2009543566A patent/JP2010514751A/ja active Pending
- 2007-12-28 HR HR20110509T patent/HRP20110509T1/hr unknown
- 2007-12-28 BR BRPI0720876-6A patent/BRPI0720876A2/pt not_active IP Right Cessation
- 2007-12-28 WO PCT/IB2007/055326 patent/WO2008081399A2/en not_active Ceased
- 2007-12-28 US US12/521,453 patent/US8288435B2/en not_active Expired - Fee Related
- 2007-12-28 PT PT07859531T patent/PT2094690E/pt unknown
- 2007-12-28 ES ES07859531T patent/ES2364297T3/es active Active
- 2007-12-28 NZ NZ578642A patent/NZ578642A/en not_active IP Right Cessation
- 2007-12-28 CN CN2007800483236A patent/CN101568536B/zh not_active Expired - Fee Related
- 2007-12-28 DE DE602007013937T patent/DE602007013937D1/de active Active
-
2009
- 2009-06-17 MA MA32004A patent/MA31000B1/fr unknown
- 2009-07-27 NO NO20092762A patent/NO20092762L/no not_active Application Discontinuation
- 2009-07-27 ZA ZA200905229A patent/ZA200905229B/xx unknown
-
2011
- 2011-07-13 CY CY20111100681T patent/CY1111705T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1633433A (zh) * | 2001-05-05 | 2005-06-29 | 史密斯克莱·比奇曼公司 | N－芳酰基环胺 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101568536B (zh) | 作为食欲素受体拮抗剂的2-氮杂-双环[3.1.0]己烷衍生物 | |
| US8236801B2 (en) | 2-aza-bicyclo[2.2.1]heptane derivatives | |
| EP2185512B1 (en) | Trans-3-aza-bicyclo[3.1.0]hexane derivatives | |
| US8106215B2 (en) | 3-aza-bicyclo[3.3.0]octane compounds | |
| US8063099B2 (en) | Trans-3-aza-bicyclo[3.1.0]hexane derivatives | |
| US20100016401A1 (en) | 3-aza-bicyclo[3.1.0]hexane derivatives | |
| US20110105491A1 (en) | Thiazolidine compounds as orexin receptor antagonists | |
| CA2693820A1 (en) | 2-aza-bicyclo[3.3.0]octane derivatives | |
| WO2010038200A1 (en) | Oxazolidine compounds as orexin receptor antagonists | |
| HK1136554B (en) | 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111228 Termination date: 20131228 |